TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imugene ( (AU:IMU) ) just unveiled an update.
Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an allogeneic CD19 CAR T therapy for relapsed diffuse large B-cell lymphoma (DLBCL). The trial has achieved an 82% overall response rate, with seven complete and seven partial responses among the patients, many of whom had previously failed multiple lines of therapy. This development highlights the potential of azer-cel in addressing high unmet needs in aggressive blood cancer treatment. The trial is expanding to include CAR T naïve patients with various non-Hodgkin lymphomas, showing meaningful clinical activity and durability of response.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is involved in creating allogeneic off-the-shelf CAR T-cell therapies, addressing challenges such as geographical access, manufacturing complexity, and treatment timelines.
YTD Price Performance: -72.58%
Average Trading Volume: 2,334,141
Technical Sentiment Signal: Sell
Current Market Cap: A$108.8M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.